Stress Management Therapy for Meniere's Disease

NCT ID: NCT01099046

Last Updated: 2010-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Attacks in Meniere's disease, characterized by vertigo and hearing loss, are well known to occur repeatedly under stressed environment. Hitherto, its pathology was revealed to be inner ear hydrops through human temporal bone studies in 1938. For the pathogenesis of inner ear hydrops resulting in Meniere's attacks, plasma vasopressin elevation due to stress and V2 receptor overexpression in the inner ear could be essential as a basis of this disease. In the present study, we'd like to find the effective and feasible way to reduce plasma vasopressin level in patients with Meniere's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

For the pathogenesis of inner ear hydrops resulting in Meniere's attacks, plasma vasopressin elevation due to stress and V2 receptor overexpression in the inner ear could be essential as a basis of this disease. In the present study, we'd like to find the effective and feasible way to reduce plasma vasopressin level in patients with Meniere's disease.

METHODS:

We estimate to enroll 200 Meniere's patients to four study groups in a randomized controlled trial at Osaka University Hospital during this study period 2010-2015. Patients are diagnosed as Meniere's patients according to the 1995 AAO-HNS criteria. Group-I consists of 50 patients who receive just traditional oral intake medication including anti-diuretics. Group-II consists of 50 patients who receive both medication and water intake (at least 2.0 litters per day). Group-III consists of 50 patients who receive both medication and tympanic tubing (under local anesthesia). Group-IV consists of 50 patients who receive both medication and sleep well (regular sleep program under dark everynight). Additional factors to medication in each group are supposed to have influence on hypothalamus. We follow up all these patients at least 12 months and evaluate stress, psychological and dizziness conditions using a couple of questionnaires. We also examine changes in plasma vasopressin level of patients in each group.

ESTIMATED RESULTS:

Through this study, we can understand the most effective and feasible way to reduce plasma vasopressin level in patients with Meniere's disease. Much more Meniere's patients may be rescued without invasive surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meniere's Disease Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

medication only

medication = anti-diuretics

Group Type NO_INTERVENTION

Lifestyle

Intervention Type BEHAVIORAL

water intake, tympanic tubing, regular sleep

medication + water intake

anti-diuretics + water intake (at least 2.0 litters per day)

Group Type ACTIVE_COMPARATOR

Lifestyle

Intervention Type BEHAVIORAL

water intake, tympanic tubing, regular sleep

medication + tympanic tubing

anti-diuretics + tympanic tubing (under local anesthesia)

Group Type ACTIVE_COMPARATOR

Lifestyle

Intervention Type BEHAVIORAL

water intake, tympanic tubing, regular sleep

medication + regular sleep

anti-diuretics + regular sleep (regular sleep program under dark everynight)

Group Type ACTIVE_COMPARATOR

Lifestyle

Intervention Type BEHAVIORAL

water intake, tympanic tubing, regular sleep

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lifestyle

water intake, tympanic tubing, regular sleep

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stress Management Therapy (SMT)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed as Meniere's patients according to the 1995 AAO-HNS criteria are included into this study.

Exclusion Criteria

* Patients refused our prepared four kinds of treatments are excluded from this study.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Osaka University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Otolaryngology & Head and Neck Surgery, Osaka University School of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tadashi Kitahara, M.D.,Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Otolaryngology, Osaka University, School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Otolaryngology, Osaka University, School of Medicine

Suita, Osaka, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tadashi Kitahara, M.D.,Ph.D.

Role: CONTACT

+81-6-6879-3951 ext. 3951

Arata Horii, M.D.,Ph.D.

Role: CONTACT

+81-6-6879-3954 ext. 3954

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tadashi Kitahara, M.D.,Ph.D.

Role: primary

+81-6-6879-3951 ext. 3951

Arata Horii, M.D.,Ph.D.

Role: backup

+81-6-6879-3954 ext. 3954

References

Explore related publications, articles, or registry entries linked to this study.

Kitahara T, Maekawa C, Kizawa K, Horii A, Doi K. Plasma vasopressin and V2 receptor in the endolymphatic sac in patients with delayed endolymphatic hydrops. Otol Neurotol. 2009 Sep;30(6):812-9. doi: 10.1097/MAO.0b013e3181b11db5.

Reference Type BACKGROUND
PMID: 19638944 (View on PubMed)

Kitahara T, Doi K, Maekawa C, Kizawa K, Horii A, Kubo T, Kiyama H. Meniere's attacks occur in the inner ear with excessive vasopressin type-2 receptors. J Neuroendocrinol. 2008 Dec;20(12):1295-300. doi: 10.1111/j.1365-2826.2008.01792.x.

Reference Type BACKGROUND
PMID: 19094077 (View on PubMed)

Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study. Laryngoscope. 2008 May;118(5):854-61. doi: 10.1097/MLG.0b013e3181651c4a.

Reference Type BACKGROUND
PMID: 18520184 (View on PubMed)

Horii A, Uno A, Kitahara T, Mitani K, Masumura C, Kizawa K, Kubo T. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res. 2007;17(1):1-8.

Reference Type BACKGROUND
PMID: 18219099 (View on PubMed)

Horii A, Kitahara T, Uno A, Kondoh K, Morihana T, Okumura S, Nakagawa A, Mitani K, Masumura C, Kubo T. Vestibular function and vasopressin. Acta Otolaryngol Suppl. 2004 Aug;(553):50-3. doi: 10.1080/03655230410017661.

Reference Type BACKGROUND
PMID: 15277036 (View on PubMed)

Kitahara T, Okamoto H, Fukushima M, Sakagami M, Ito T, Yamashita A, Ota I, Yamanaka T. A Two-Year Randomized Trial of Interventions to Decrease Stress Hormone Vasopressin Production in Patients with Meniere's Disease-A Pilot Study. PLoS One. 2016 Jun 30;11(6):e0158309. doi: 10.1371/journal.pone.0158309. eCollection 2016.

Reference Type DERIVED
PMID: 27362705 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

yk19700512

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Laser Acupuncture for Meniere Disease
NCT06544434 RECRUITING PHASE2
OTO-104 for Meniere's Disease
NCT01084525 COMPLETED PHASE1
Prevention of Noise-induced Hearing Loss
NCT02049073 WITHDRAWN PHASE1/PHASE2